Pharmaceutical Products / Drugs Technology Offers

Ivan Rodriguez Rosello posted this:
Licensing Manager at Universidad de Alicante

Antibacterial alternative to antibiotics, with high specificity against Escherichia coli The "Molecular Microbiology" research group at the University of Alicante has modified several phage proteins (Poll-N and UK-C) that have high specificity against Escherichia coli (E. coli), but not against other Gram-negative (G-) bacteria. For these reasons, their use as a specific antimicrobial against E. coli is potentially interesting, especially in the case of contaminated food, cosmetics or water. It would also be useful in the treatment of diseases (infections) caused by E. coli. The presence of a histidine tail attached to the phage proteins not only facilitates their purification but also improves lysis efficiency without the need of cell permeabilization treatments. Companies interested in the commercial exploitation of the technology through license agreements and/or technical cooperation are sought.

University of Vigo posted this:

Procedure for the extraction of biosurfactants contained in corn steep liquors Nowadays, most of the pharmaceutical and cosmetic products in the market contain chemically synthesized surfactants in its composition. In many cases, these surfactants are the same as those used in regular cleanup activities. In order to get more natural and biocompatible products, it would be interesting to include natural surfactants instead of chemical surfactants in the preparation of these pharmaceutical and cosmetic products. These biosurfactants are also present in the formulation of greener nanoparticles, replacing the chemical surfactants currently used in the preparation thereof. Most biosurfactants have antimicrobial activity, which would improve the properties of certain nanoparticles, as well as many pharmaceutical and cosmetic products. The main disadvantage of biosurfactants industrial production is related to the high cost compared to chemically synthesized surfactant production. The solution proposed by the Chemical Engineering research group at the University of Vigo, is the development of eco-friendly simple extraction of biosurfactant from a corn wet-milling industry byproduct, such as corn wash liquors, better known as "corn steep liquor (CSL)", which could compete in terms of cost production with its chemical counterparts.

National Cancer Institute CRO Aviano posted this:

HPLC device for high-volume samples analysis Fluidic device that allows high sample volume injection in HPLC systems and provides an automated purification step, reducing sensitivity problems and facilitating the analysis of extracted compounds from complex matrix.

National Cancer Institute CRO Aviano posted this:

CHEMIOTHERAPY: IMATINIB DRUG MONITORING The effectiveness of many anticancer drugs varies greatly from patient to patient, with risks of incorrect dosages and adverse side effects. The invention provides for the first time an electrochemical method to measure the concentration of the drug Imatinib in patient's plasma and then to establish the optimal dose, with an on site test readable in real time.

National Cancer Institute CRO Aviano posted this:

Mechanisms of p53 inactivation in TP53 wild type tumors and factors affecting sensitivity to MDM2 inhibitors The research group led by Dr Roberta Maestro demonstrated that the overexpression of the protein Twist, detectable in a large fraction of sarcomas but also in a fraction of carcinomas, facilitates the MDM2-mediated degradation of p53 by making p53 more susceptible to MDM2 attack. The p53:MDM2 interplay is the target of a number of compounds currently under clinical trials. These compounds (MDM2i) are aimed at alleviating p53 from MDM2-mediated degradation and hence at restoring the p53 tumor suppressive activity. Maestro and coworkers gathered data indicating that the expression of Twist may significantly impact on the activity of these drugs.

UACOOPERA University of Aveiro posted this:
Technology Transfer Office at uacoopera

Immunoglobulin Y Purification, Its Products And Uses This invention describes a purification process of immunoglobulin Y from egg yolk in three stages, by applying precipitation methods, liquid-liquid extraction and ultracentrifugation. The present process allows to obtain immunoglobulin Y of high quality and with a purity >95%, in a simple and economic way, and applicable at an industrial scale.

Consejo Superior de Investigaciones Científicas posted this:

Oleuropein obtaining procedure: high purity antioxidant CSIC has developed a reliable and effective method for obtaining oleuropein from olive leaf: comprising a pretreatment that increases the concentration of oleuropein in the extracts over other known methods and achieving this bioactive compound with a purity superior of 70%. Industrial partners from the food and pharmaceutical industry are being sought to collaborate through a patent licence agreement. An offer for Patent Licensing

Consejo Superior de Investigaciones Científicas posted this:

OPTOBIOTICS: Novel antibacterial proteins activated by blue light CSIC has developed a chimeric protein that, when expressed in bacteria, changes its structure upon absorption of blue light, thus generating protein aggregates (amyloids) that inhibit bacterial growth Industrial partners from the pharmaceutical industry are being sought to collaborate through a patent licence agreement An offer for Patent Licensing

Ukrainian Laboratories posted this:

Computer aided drug discovery services Otava Research Institute helps researchers around the world develop advanced solutions for the variety of research projects maximizing their efficiencies, and, most of all, respecting their budgets. Our experts are involved in the development of leading compounds at any stage of the R&D process: starting from target identification to lead optimization

Ivan Rodriguez Rosello posted this:
Licensing Manager at Universidad de Alicante

New multifunctional material for controlled-drug-release implants The "Advanced Materials" research group at the University of Alicante has developed a foamed material comprising three phases: a structural matrix, at least one host phase, and a fluid. This material is characterized by the fact that the structural matrix comprises a plurality of interconnected porous cavities, the host phase(s) is/are housed within at least one porous cavity of the structural matrix and the fluid is housed within the porous cavities. The host phase(s) can be housed within the porous cavities of the structural matrix without maintaining any union or maintaining discrete unions with the latter. The structural matrix may consist of a material of a metallic, polymeric, ceramic nature or mixtures thereof. Meanwhile, the host phase(s) is/are a functional material, the fluid being a liquid or a gas. These materials have many potential uses, among which ones is as an implant material, with the additional possibility of exerting a controlled release of drugs. Companies interested in commercial exploitation of this material through a patent license agreement are sought.

Consejo Superior de Investigaciones Científicas posted this:

Overcoming resistance to Beta-lactam antibiotics in Bacterial species CSIC and the University of Würzburg have developed a new method to eliminate antibiotic-resistant bacterial infections using classical antibiotics previously discarded due the occurrence of antibiotic resistance. Industrial partners from the pharmaceutical industry are being sought to collaborate through a patent licence agreement. An offer for Patent Licensing

Consejo Superior de Investigaciones Científicas posted this:

Purine derivatives for the treatment of neurodegenerative diseases CSIC has synthesized several substituted purine derivatives that are capable of inhibiting the activity of the CDC7 kinase. This inhibitory activity makes them useful for the treatment of neurological diseases. The compounds developed are, therefore, a new therapeutic alternative for Alzheimer's disease, amyotrophic lateral sclerosis or frontotemporal dementia. Industrial partners from pharmaceutical industry are being sought to develop and commercialized the compounds through a patent licence agreement. An offer for Patent Licensing

Consejo Superior de Investigaciones Científicas posted this:

New treatment for epidermolysis bullosa and fibrosis CSIC, Carlos III University of Madrid and CIEMAT have repositioned drugs that stimulate endogline expression and modulate the TGF-β route for a new clinical use in the treatment of fibrosis, such as epidermolysis bullosa (EB). EB includes a heterogeneous group of rare hereditary diseases of the skin in which in its infantile incidence the patients are known as "butterfly children". It is a new therapy for a rare pathology, with potential in a wide spectrum of fibrosis, which would improve the possibilities of treatment of patients, improving their quality of life. Industrial partners from the pharmaceutical industry are being sought for its development in a wide variety of fibrotic pathologies through a patent licence agreement. An offer for Patent Licensing

Consejo Superior de Investigaciones Científicas posted this:

Control of neurodegenerative diseases with benzothiazole-benzamide derivatives Control of neurodegenerative diseases with benzothiazole-benzamide derivatives CSIC has developed a group of heterocyclic compounds derived from a privileged structural nucleus with the capacity to inhibit the LRRK2 enzyme. This inhibitory activity makes them useful in the treatment of neurodegenerative diseases affected by this enzyme, among which Parkinson's disease and Alzheimer's disease stand out. Pharmaceutical companies interested in the development and commercialization of these compounds under a patent license are sought. An offer for Patent Licensing

Consejo Superior de Investigaciones Científicas posted this:

Compounds for the treatment and prevention of immune-mediated inflammatory diseases CSIC and the University of Athens have found that secoiridoids, such as oleacein and oleocanthal, are useful to prevent or treat illnesses that results in immune-mediated gastrointestinal alterations. A company dealing with pharmaceutical or nutraceutical compositions is sought for licensing agreement. An offer for Patent Licensing

Pharmaceutical Products / Drugs Technology Offers

Innovation Resources

Sitemaps

Support

Company

Top Posts Categories

Recognitions

Pharmaceutical Products / Drugs Technology Offers

Recognitions

Follow us